PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance
Science Immunology · 2025
DOI: 10.1126/sciimmunol.adn4302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, 2025. Verfasst von Cheng Zhong und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Phagocytosis, Macrophages, Membrane Glycoproteins, Tumor Escape. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Cancer immunotherapies exhibit impressive efficacy in some cancers but show only limited benefits for refractory hematological malignancies. The complex immune escape mechanisms of hematological cancers remain unclear. Here, we found that P-selectin glycoprotein ligand 1 (PSGL-1) was highly expressed by hematological cancers and negatively correlated with cancer prognosis. PSGL-1 deficiency in tumors suppressed the progression of multiple mouse models of hematological cancer by promoting infiltration of macrophages and their phagocytic activity. Tumor PSGL-1 inhibited the interaction between tumor ICAM-1 and CD11a/CD18 integrin (LFA-1) in macrophages, thereby suppressing prophagocytic signaling downstream of LFA-1. A humanized antibody targeting human PSGL-1 (αhPSGL-1) efficiently triggered macrophage phagocytosis of human hematological malignancies in vitro and slowed cancer progression in vivo. Additionally, PSGL-1 blockade potentiated the efficacy of doxorubicin chemotherapy and anti-CD47 and anti-CD38 antibody therapy. Therefore, PSGL-1 is a previously undescribed phagocytosis checkpoint, and targeting PSGL-1 could be a promising immunotherapy strategy for treating hematological malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
- Jinfeng Laboratory, Chongqing, China.
- GMU-GIBH Joint School of Life Sciences, Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
- Hangzhou Medimscience Biomedical Technology Co. Ltd., Hangzhou, China.
- Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
ORCID-Profile: Cheng Zhong, Lixiang Wang, Yujia Liu, Xinyu Wang, Zijin Xia, Yiyi Li, Yao Zhang, Jing Liao, Xianmiao Wang, Chenyang Liao, Chunliu Huang, Xiumei Wang, Chengzhou Mao, Yongyi Feng, Congzhou Luo, Wenhao Mai, Hongrui Song, Yue Sheng, Yingyi He, Xiaolei Wei, Hui Zhang, Hong Yuan, Wei Yi, Jun Chen
Zitieren
APA
Zhong, C., Wang, L., Liu, Y., Wang, X., Xia, Z., Li, Y., Zhang, Y., Liao, J., Wang, X., Liao, C., Huang, C., Wang, X., Mao, C., Feng, Y., Luo, C., Mai, W., Song, H., Sheng, Y., He, Y., …, & Chen, J. (2025). PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance. Science Immunology. https://doi.org/10.1126/sciimmunol.adn4302
Vancouver
Zhong C, Wang L, Liu Y, Wang X, Xia Z, Li Y, et al. PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance. Science Immunology. 2025. doi:10.1126/sciimmunol.adn4302
BibTeX
@article{Zhong2025,
author = {Zhong, Cheng and Wang, Lixiang and Liu, Yujia and Wang, Xinyu and Xia, Zijin and Li, Yiyi and Zhang, Yao and Liao, Jing and Wang, Xianmiao and Liao, Chenyang and Huang, Chunliu and Wang, Xiumei and Mao, Chengzhou and Feng, Yongyi and Luo, Congzhou and Mai, Wenhao and Song, Hongrui and Sheng, Yue and He, Yingyi and Wei, Xiaolei and Zhang, Hui and Yuan, Hong and Yi, Wei and Chen, Jun},
title = {PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance},
journal = {Science Immunology},
year = {2025},
doi = {10.1126/sciimmunol.adn4302}
}
EUVIMED